--- title: "Kisspeptin-10: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/kisspeptin-10 description: "Kisspeptin-10: dosing protocols, mechanism & side effects, 597 PubMed results. Compare 3 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: Kisspeptin-10 molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # Kisspeptin-10 Hormones & Endocrine (Non-GH) (https://www.bodyhackguide.co/wiki#cat-hormones-&-endocrine-(non-gh))Phase 2 Also known as: Kisspeptin Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date. The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Image: Optimum Formula logo (https://optimumformula.co/wp-content/uploads/2025/07/LOGO-OPTIMUM-NEW.png) Lowest price per mg $4.00/mg $39.99 for 10mg at Optimum Formula · Buy at OF: https://optimumformula.co/product/kisspeptin-10/?ref=ruyhjwqh Half-life: ~4 minutes (KP-10, plasma) - reflecting rapid peptidase degra… MW: 1302.46 g/mol CAS: 374683-28-0 597 PubMed results (https://pubmed.ncbi.nlm.nih.gov/?term=kisspeptin%20GnRH%20reproductive%20axis) Last reviewed: May 4, 2026 ## Overview ### At A Glance Mechanism Kisspeptin-10 signals through a single G-protein-coupled receptor, KISS1R (formerly GPR54), expressed prominently on GnRH neurons in the hypothalamus and at lower levels in multiple peripheral tissues including placenta, gonads, and the central nervous system reward circuitry. Th… Half-Life ~4 minutes (KP-10, plasma) - reflecting rapid peptidase degradation. The downstream LH/FSH response nonetheless persists ~1-2 hours after a dose. For comparison, kisspeptin-54 has a measured plasma half-life of ~27 minutes. Potential Benefits LH/FSH stimulation Testosterone support Fertility enhancement Sexual arousal HPG axis activation Safety Notes Common Mild flushing Nausea Headache LH/testosterone surge (expected) ### Mechanism of Action Kisspeptin-10 signals through a single G-protein-coupled receptor, KISS1R (formerly GPR54), expressed prominently on GnRH neurons in the hypothalamus and at lower levels in multiple peripheral tissues including placenta, gonads, and the central nervous system reward circuitry. The pharmacology is elegant and relatively simple in mechanism but drives a complex downstream physiology: **Primary Hypothalamic Effect — GnRH Release:** KISS1R activation is coupled predominantly to Gαq/11, which activates phospholipase C, generates inositol trisphosphate (IP3) and diacylglycerol (DAG), raises intracellular calcium, and triggers GnRH release from GnRH neuron terminals in the median eminence. Kisspeptin is currently understood to be the obligate upstream driver of pulsatile GnRH release — the GnRH neurons themselves generate the pulse timing, but kisspeptin input controls whether and how strongly they fire. Under physiological conditions, kisspeptin neurons in the arcuate nucleus (the "KNDy" neurons, which also express neurokinin B and dynorphin) fire synchronously to generate GnRH pulses, while kisspeptin neurons in the preoptic area (AVPV) drive the GnRH surge responsible for the mid-cycle LH surge in females. **Downstream HPG Axis Activation:** GnRH released from the median eminence travels through the hypophyseal portal circulation to the anterior pituitary, where it stimulates gonadotroph cells to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates gonadal testosterone or estrogen production and triggers ovulation in females; FSH drives spermatogenesis in males and follicular development in females. The entire cascade — KP-10 → GnRH → LH/FSH → gonadal steroids → gametogenesis — takes roughly 20-60 minutes from IV or SC kisspeptin administration to measurable LH/FSH rise in plasma. **Selectivity and Signaling Bias:** KP-10 is a high-affinity full agonist at KISS1R with IC50 in the low-nanomolar range. There is no significant cross-reactivity with other GPCRs. Signaling bias studies suggest that kisspeptin preferentially engages Gαq pathways over β-arrestin recruitment, which may contribute to its relatively favorable desensitization profile compared to GnRH analogs. Continuous high-dose kisspeptin exposure does eventually produce GnRH-axis downregulation, but pulsatile or intermittent dosing appears to maintain responsiveness. **Extrapituitary Effects:** - **Limbic system (amygdala, hippocampus, cingulate cortex):** KISS1R expression in limbic structures mediates kisspeptin's effects on sexual desire, emotional processing, and mood. Comninos and colleagues at Imperial College have shown using fMRI that kisspeptin administration in men enhances brain activity in reward/arousal circuits in response to sexual and romantic cues, and attenuates activity in regions associated with negative mood and anxiety ([Comninos et al., 2017]). - **Gonads (direct):** KISS1R is expressed on theca and granulosa cells of the ovary and on Leydig cells of the testis; direct local kisspeptin signaling may modulate steroidogenesis and gamete maturation, though the physiological significance of these peripheral actions in kisspeptin-treated subjects is uncertain. - **Placenta:** Kisspeptin is produced in large amounts by trophoblasts and is thought to regulate trophoblast invasion and placental development. This is why plasma kisspeptin concentrations rise dramatically in pregnancy. **Pharmacokinetics:** KP-10 administered subcutaneously or intravenously has a plasma half-life of approximately 4 minutes — extremely short, reflecting rapid peptidase degradation. Despite this short half-life, the downstream LH/FSH response lasts 1-2 hours because the pituitary gonadotrophs require time to transcribe and secrete the hormones triggered by the initial GnRH pulse. Continuous infusion or repeated boluses produce sustained axis activation; single doses produce a single pulse-like LH/FSH rise. This short half-life is why kisspeptin preparations are usually administered either as continuous subcutaneous infusions (for ovulation induction or sustained axis stimulation) or as frequent bolus doses (for pulsatile stimulation mimicking endogenous physiology). **Longer-Acting Forms:** Researchers have developed both KP-54 (which has slightly longer half-life but still on the order of 30 minutes) and engineered kisspeptin analogs with PEGylation or other half-life-extending modifications. MVT-602 (from Myovant Sciences) is a kisspeptin analog with an approximate 60-90 minute half-life being investigated for clinical use. For most peptide-community use, plain KP-10 remains the most accessible form. ### Overview Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date. The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Its true reproductive function wasn't understood until 2003, when two independent research groups — one led by Nicolas de Roux in Paris and another by Stephanie Seminara at Massachusetts General Hospital — discovered that loss-of-function mutations in the G-protein-coupled receptor GPR54 (now named KISS1R) caused hypogonadotropic hypogonadism with failure of puberty. This finding transformed kisspeptin from an obscure tumor-biology gene into the gatekeeper of the entire hypothalamic-pituitary-gonadal (HPG) axis (de Roux et al., 2003 (https://pubmed.ncbi.nlm.nih.gov/14573733/), Seminara et al., 2003 (https://pubmed.ncbi.nlm.nih.gov/14573733/)). Kisspeptin is synthesized as a 145-amino-acid precursor prohormone that is processed into several bioactive peptides: kisspeptin-54 (KP-54, the longest form), kisspeptin-14, kisspeptin-13, and kisspeptin-10. KP-10 retains essentially all of the biological potency of the parent molecule at the KISS1R receptor, making it the most practical form for research and therapeutic exploration — it is smaller, more stable, easier to synthesize, and equally efficacious. Kisspeptin neurons in the hypothalamus (located in the arcuate nucleus and the preoptic area / AVPV) project to GnRH neurons and release kisspeptin as the essential upstream stimulus that drives GnRH release. Without kisspeptin signaling, GnRH neurons fire infrequently or not at all, and the entire reproductive axis — LH, FSH, testosterone, estrogen, ovulation, spermatogenesis — shuts down. This is why congenital KISS1R mutations cause such a dramatic reproductive phenotype despite the rest of the HPG axis being intact ([Messager et al., 2005]). In current clinical and research practice, kisspeptin (usually as KP-10 or KP-54) is being investigated for a range of reproductive applications: as a diagnostic probe for the integrity of the HPG axis (an alternative to or supplement to GnRH stimulation testing), as an ovulation trigger in in-vitro fertilization cycles (where it may reduce ovarian hyperstimulation syndrome risk compared to hCG), as a therapy for hypothalamic amenorrhea and functional hypothalamic hypogonadism, and as an investigational treatment for hypoactive sexual desire disorder (HSDD), with emerging work on mood and anxiety effects as well. Kisspeptin is not currently approved for any indication in the United States, but Phase II data from Imperial College London and other centers have been promising enough that pharmaceutical development is underway ([Dhillo et al., 2005], [Abbara et al., 2015]). Off-label and peptide-community interest in KP-10 centers on two use cases. First, men using suppressive regimens — testosterone replacement therapy, anabolic steroid cycles, or GnRH-axis-affecting drugs — sometimes use KP-10 during "post-cycle" recovery phases on the theory that stimulating endogenous GnRH release may accelerate HPG axis recovery faster than the conventional Gonadorelin (https://www.bodyhackguide.co/compound/gonadorelin) (GnRH) or HCG (Human Chorionic Gonadotropin) (https://www.bodyhackguide.co/compound/hcg) approaches. The evidence base for this use is thin — kisspeptin's efficacy in restoring suppressed axes after exogenous androgens has not been formally studied — but mechanistically plausible. Second, some researchers and a small community of users are interested in kisspeptin's effects on sexual desire and mood, which appear to be separable from its reproductive effects and mediated by kisspeptin receptor expression in limbic structures like the amygdala ([Comninos et al., 2017]). KP-10 is a legitimate research tool with meaningful clinical promise and an unusually well-characterized physiological mechanism. Unlike many grey-market peptides, the clinical evidence base is growing and the safety profile in short-term human trials at reproductive-axis doses has been clean. This entry covers KP-10's known biology, its current and investigational uses, and the considerable uncertainties that remain — particularly around long-term dosing, optimal regimens for axis recovery, and whether peripheral KP-10 administration reproduces the physiological effects of endogenous kisspeptin neuron firing. ### Potential Research Fields Hypogonadotropic hypogonadism Fertility Sexual dysfunction Puberty disorders ## Chemical Information IUPAC Name Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 CAS Number 374683-28-0 Molecular Formula C63H83N17O13 Molecular Mass 1302.46 g/mol Image: Kisspeptin-10 molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44249291/PNG?image_size=300x300) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/44249291 Amino Acid Sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (single-letter: YNWNSFGLRF-NH2). Human kisspeptin-10 is the C-terminally amidated decapeptide corresponding to metastin/KISS1 residues 45-54 (KISS1 112-121); the C-terminal Arg-Phe-NH2 is the RFamide motif required for KISS1R (GPR54) activation. Formula C63H83N17O14; CAS 374675-21-5. ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, route, how often and how long - A titration schedule - Beginner, intermediate and advanced protocols - Reconstitution and handling notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications **Absolute contraindications:** - Hormone-sensitive cancers — prostate cancer, hormone-receptor-positive breast cancer, endometrial cancer. Kisspeptin drives endogenous sex steroid production, which can accelerate these malignancies. - Active pregnancy (outside of specifically supervised ovulation-induction protocols) - Known hypersensitivity to kisspeptin preparations - Age < 18 without pediatric endocrinology involvement - Untreated or poorly controlled pituitary adenomas (particularly gonadotropin-secreting adenomas) **Strong relative contraindications:** - Severe uncontrolled hypertension - Recent cardiovascular event (MI, stroke within 6 months) - Moderate-to-severe liver or kidney dysfunction (peptide clearance uncertain) - Active attempt at conception when timing is not desired (kisspeptin substantially raises fertility potential) - Personal history of estrogen-driven conditions (severe endometriosis, estrogen-responsive fibroids) where rising estrogen from re-activated axis may worsen symptoms - Individuals on hormonal therapies for gender transition (feminizing or masculinizing) who are not attempting to activate their endogenous axis — kisspeptin will counteract the hormonal regimen goals **Drug interactions:** - **Opioids (chronic high-dose):** Opioids suppress GnRH release downstream of kisspeptin signaling. Kisspeptin effect may be blunted in chronic opioid users. - **GnRH antagonists (cetrorelix, degarelix) or GnRH agonists at suppressive doses (leuprolide):** Pharmacological antagonism; do not combine. - **Androgen deprivation therapy for prostate cancer:** Absolute contraindication to kisspeptin. - **Aromatase inhibitors (anastrozole, letrozole):** Not a direct interaction but will alter the estrogen component of the axis response. - **Dopamine agonists (bromocriptine, cabergoline):** Dopamine suppresses kisspeptin neuron activity; chronic high-dose dopaminergics may reduce kisspeptin effect. - **Exogenous androgens (testosterone, SARMs, anabolic steroids) during active dosing:** Strong negative feedback will overwhelm upstream stimulation. Kisspeptin makes sense during recovery phases, not during active androgen suppression. **Stop using if:** - Any new breast lump, unusual bleeding, or prostate concerns - New or worsening mood symptoms - Severe headache, visual changes, or symptoms suggestive of pituitary pathology - Pregnancy (confirmed or suspected, outside of specific supervised protocols) - Unexplained sudden blood pressure rise **Monitoring:** - Baseline labs before starting: LH, FSH, total and free testosterone, estradiol, prolactin, SHBG, TSH, CBC, metabolic panel - Mid-cycle labs at 4-6 weeks: LH, FSH, total and free testosterone, estradiol - End-cycle labs at 8-12 weeks: full panel repeat - For women: menstrual cycle tracking; early pregnancy test if any cycle irregularity - For men in recovery phases: semen analysis at 3-6 months if fertility is a concern **Medical Supervision:** Kisspeptin is a legitimate research and emerging clinical tool. Users with access to endocrinology-literate physicians should strongly prefer supervised rather than independent use — axis recovery, desire effects, and any adverse events are far better managed with lab monitoring and clinical oversight. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $39.99 up to $54.99 Best $/mg $3.9990 Vendors 3 Listings 3 vial Dosage Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Kisspeptin | vial | 1 vial ● In Stock | $54.99 | — | — | Buy: https://disguisedalpha.com/product/kisspeptin/?coupon=reddit | | Image: Optimum Formula logo (https://optimumformula.co/wp-content/uploads/2025/07/LOGO-OPTIMUM-NEW.png) Optimum Formula (https://www.bodyhackguide.co/vendors/optimum-formula) 100: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | Kisspeptin-10 10mg | vial | 1 vial ● In Stock | $39.99 BEST | $4.00 | REDDIT | Buy: https://optimumformula.co/product/kisspeptin-10/?ref=ruyhjwqh | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | Kisspeptin-10 5mg | vial | 5mg vial ● In Stock | $39.99 | $8.00 | CHON | Buy: https://www.vandl-labs.com/product/kisspeptin-10/?ref=choncho | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Kisspeptin-10. Current low $39.99 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Apr 6, 2026 · 3 data points ## Price History 3 data points ### Vendors Selling Kisspeptin-10 #### VANDL Labs 1 listing · from $39.99 https://www.bodyhackguide.co/vendors/vandl-labs #### Optimum Formula 4.9 1 listing · from $39.99 https://www.bodyhackguide.co/vendors/optimum-formula #### Disguised Alpha 1 listing · from $54.99 https://www.bodyhackguide.co/vendors/disguised-alpha How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### Gonadorelin Hormones & Endocrine (Non-GH) FDA Approved Gonadorelin is the synthetic, pharmaceutically manufactured version of endogenous gonadotropin-releasing hormone (GnRH) — a ten-amino-acid decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) first isolated, sequenced, and synthesized by Andrew V. t½ ~2-10 minutes (plasma; rapid enzymatic degradation by peptidases) 100-300 mcg 473 PubMed View Profile https://www.bodyhackguide.co/compound/gonadorelin ### HMG (Human Menopausal Gonadotropin) HMG, or human menopausal gonadotropin, is not a synthetic research chemical. t½ Elimination half-life for follicle-stimulating hormone of 11 to 13 hours in the multiple-dose phase, similar for subcutaneous and intramuscular routes (Menopur US prescribing information) Preclinical View Profile https://www.bodyhackguide.co/compound/hmg ### Oxytocin Oxytocin is a nine-amino-acid cyclic peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) synthesized in magnocellular neurons of the hypothalamic paraventricular (PVN) and supraoptic nuclei (SON), then transported along axons to the posterior pituitary for release into systemic circulation. t½ ~1-6 minutes (plasma); central/behavioral effects outlast plasma clearance, typically ~30-120 minutes after intranasal dosing 602 PubMed View Profile https://www.bodyhackguide.co/compound/oxytocin View Full Dosage Guide → Protocols, calculator & safety for Kisspeptin-10 https://www.bodyhackguide.co/guides/dosage/kisspeptin-10 ### Related Articles All Posts (https://www.bodyhackguide.co/blog) #### How to Make a Peptide Nasal Spray at Home: The Complete DIY Guide (2026) A full DIY protocol for turning peptides into nasal sprays, with Semax, Selank, oxytocin, DSIP, and BPC-157 as worked examples. It covers reconstitution math, sterile technique, storage, pH and tonicity, and safety in 11 steps. 4/21/2026 https://www.bodyhackguide.co/blog/how-to-make-peptide-nasal-spray-at-home ### Lowest Price per mg Optimum Formula $39.99($4.00/mg) 3 vendors · 3 listings ### Research Score 100 597 PubMed results ### Quality Indicators Data Completeness 100% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings COA Verification 4 Verified COAs 1 Vendors w/ COA Latest test: 3/1/2026 Research Volume 597 PubMed results Well-researched compound ### Quick Facts Half-Life Molecular Weight 1302.46 g/mol CAS Number 374683-28-0 Trial Phase Phase 2 ### Safety Profile Low Risk Common Side Effects - • Mild flushing - • Nausea - • Headache - • LH/testosterone surge (expected) Stop Use If - Hormone-sensitive cancers - Pregnancy (outside clinical protocol) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What exactly does kisspeptin do that makes it so important? Kisspeptin is the master upstream regulator of the entire reproductive axis. It stimulates GnRH neurons in the hypothalamus to release GnRH, which then drives LH and FSH release from the pituitary, which then drives testosterone, estrogen, spermatogenesis, and ovulation from the gonads. Without kisspeptin signaling, the whole axis goes silent - people born with inactivating mutations in the kisspeptin receptor (KISS1R) fail to enter puberty. Because kisspeptin sits at the top of this cascade, exogenous kisspeptin can drive the entire axis downstream when administered, making it uniquely powerful among reproductive peptides. How is KP-10 different from KP-54? Both are endogenously produced kisspeptin peptides - KP-54 is the longer precursor cleavage product (54 amino acids), and KP-10 is the C-terminal decapeptide that retains essentially all the biological activity. KP-10 has a shorter plasma half-life (~4 minutes vs ~30 minutes for KP-54) but is functionally equivalent at the receptor. For most peptide-community use, KP-10 is more commonly available and equally effective for axis stimulation. Clinical research often uses KP-54 for applications like ovulation induction where the slightly longer half-life simplifies dosing. Can I use KP-10 during an active anabolic cycle? It will not work during active high-dose androgen administration. Exogenous androgens produce powerful negative feedback at both hypothalamus and pituitary, and this suppression overwhelms any upstream kisspeptin stimulation. KP-10 is useful during recovery phases (after exogenous androgens are cleared, typically 2-4 weeks post-cycle depending on ester) but not during active suppression. HCG, which acts directly at Leydig cell LH receptors in the testis and bypasses central suppression, is the appropriate on-cycle support for testicular function - kisspeptin becomes relevant afterward. How quickly will I feel KP-10 working? This depends on indication. For axis recovery after exogenous androgen suppression, effects are measured in lab trends over weeks - LH and FSH rises can be seen within days of starting, testosterone follows over 2-4 weeks, and full axis normalization often takes 6-12 weeks. Subjectively, most users notice returning morning erections, libido, and energy gradually over the first month rather than any dramatic acute change. For the central desire/HSDD effects, acute subjective changes (libido, emotional engagement) often occur within 1-2 hours of dosing. The axis and the limbic effects operate on different timescales. Is KP-10 safer than HCG or clomiphene for axis recovery? Short answer: side-effect profiles differ, and KP-10 looks cleanest in published trials, but no head-to-head long-term comparison study has been done. HCG maintains Leydig cell function during cycle but can desensitize LH receptors with prolonged use and does not address hypothalamic suppression. Clomiphene/enclomiphene act at the estrogen receptor and have well-documented vision and mood side effects in some users. KP-10 acts at the hypothalamus through a different mechanism without the desensitization or SERM side-effect concerns, but the long-term safety of repeated kisspeptin dosing has not been established. Most users of rigorous recovery protocols combine modalities rather than relying on any single agent. Will KP-10 make me fertile if I've been trying to conceive? Possibly yes, for both men and women. In men with suppressed axes from exogenous androgens or functional causes, kisspeptin-driven LH/FSH restoration can rebuild spermatogenesis over 3-6 months (one full spermatogenesis cycle). In women with functional hypothalamic amenorrhea, kisspeptin can restore ovulation; published trials have demonstrated live births following kisspeptin-triggered ovulation in IVF cycles. However, fertility is complicated and requires the entire reproductive system to be intact. Kisspeptin fixes upstream signaling but cannot compensate for primary gonadal failure, severe oligospermia from structural causes, or uterine/tubal factors. Fertility work should be medically supervised. Does KP-10 help with libido even if my testosterone is normal? Research suggests yes. Kisspeptin's effects on sexual desire and romantic processing operate through limbic brain regions (amygdala, hippocampus) that are pharmacologically separate from the HPG axis. Imperial College studies have shown fMRI evidence of enhanced sexual arousal circuit activation from kisspeptin even in eugonadal men, and clinical trials in women with HSDD have shown improvements in subjective desire that are not driven by testosterone or estrogen changes. This central mechanism appears to be distinct from the HPG-axis mechanism and is why kisspeptin is being pursued as a potential HSDD treatment. In practical use, some people with normal hormones experience meaningful subjective libido response to kisspeptin; others do not - individual response varies. What about kisspeptin and mood or anxiety? Preliminary research suggests kisspeptin may have anxiolytic effects and improve mood regulation in some populations, mediated through limbic kisspeptin receptors. Small trials and case studies have reported improvements in self-reported anxiety and mood during kisspeptin administration. However, this is not a clinical indication and the evidence base is much smaller than for reproductive effects. No one should substitute kisspeptin for evidence-based mental health treatment. If users notice mood benefits alongside reproductive effects, this is consistent with the emerging science but should not be the primary reason for use. Do I need to cycle KP-10? It depends on how you dose. This matters because human trials have actually shown clear tachyphylaxis under some schedules: twice-daily subcutaneous kisspeptin-54 injections in women with hypothalamic amenorrhea largely abolished the LH and FSH response within about two weeks of high-frequency bolus dosing. Spacing the same peptide out to twice-weekly avoided most of that desensitization while still raising reproductive hormones over eight weeks, and short studies of continuous KP-10 infusion have maintained responses - so the receptor does not inevitably desensitize, but frequent, sustained, high-dose bolus exposure clearly can blunt it. Because long-term data are absent, spacing doses and using defined cycles (for example, running an 8-12 week axis-recovery block around a specific goal and then discontinuing, rather than dosing indefinitely) is the prudent, conservative approach. Can women use KP-10 for axis recovery after hormonal contraceptive suppression? Possibly. Some women experience prolonged menstrual cycle irregularity after stopping long-term hormonal contraception, often reflecting functional hypothalamic suppression. Kisspeptin has shown efficacy in restoring cycles in hypothalamic amenorrhea trials and may theoretically help in post-contraceptive axis recovery. However, the evidence base for this specific application is thinner than for men's post-cycle recovery. Women considering kisspeptin for cycle restoration should ideally work with a reproductive endocrinologist and ensure that other causes of irregular cycles (thyroid, prolactinoma, PCOS) have been excluded. Pregnancy possibility during kisspeptin use in cycling women must be considered. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### Gonadorelin ### HMG (Human Menopausal Gonadotropin) ### Oxytocin Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Kisspeptin-10" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Kisspeptin-10", "description": "Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date. The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Its true reproductive function wasn't understood until 2003, when two independent research groups — one led by Nicolas de Roux in Paris and another by Stephanie Seminara at Massachusetts General Hospital — discovered that loss-of-function mutations in the G-protein-coupled receptor GPR54 (now named KISS1R) caused hypogonadotropic hypogonadism with failure of puberty. This finding transformed kisspeptin from an obscure tumor-biology gene into the gatekeeper of the entire hypothalamic-pituitary-gonadal (HPG) axis (de Roux et al., 2003, Seminara et al., 2003). Kisspeptin is synthesized as a 145-amino-acid precursor prohormone that is processed into several bioactive peptides: kisspeptin-54 (KP-54, the longest form), kisspeptin-14, kisspeptin-13, and kisspeptin-10. KP-10 retains essentially all of the biological potency of the parent molecule at the KISS1R receptor, making it the most practical form for research and therapeutic exploration — it is smaller, more stable, easier to synthesize, and equally efficacious. Kisspeptin neurons in the hypothalamus (located in the arcuate nucleus and the preoptic area / AVPV) project to GnRH neurons and release kisspeptin as the essential upstream stimulus that drives GnRH release. Without kisspeptin signaling, GnRH neurons fire infrequently or not at all, and the entire reproductive axis — LH, FSH, testosterone, estrogen, ovulation, spermatogenesis — shuts down. This is why congenital KISS1R mutations cause such a dramatic reproductive phenotype despite the rest of the HPG axis being intact ([Messager et al., 2005]). In current clinical and research practice, kisspeptin (usually as KP-10 or KP-54) is being investigated for a range of reproductive applications: as a diagnostic probe for the integrity of the HPG axis (an alternative to or supplement to GnRH stimulation testing), as an ovulation trigger in in-vitro fertilization cycles (where it may reduce ovarian hyperstimulation syndrome risk compared to hCG), as a therapy for hypothalamic amenorrhea and functional hypothalamic hypogonadism, and as an investigational treatment for hypoactive sexual desire disorder (HSDD), with emerging work on mood and anxiety effects as well. Kisspeptin is not currently approved for any indication in the United States, but Phase II data from Imperial College London and other centers have been promising enough that pharmaceutical development is underway ([Dhillo et al., 2005], [Abbara et al., 2015]). Off-label and peptide-community interest in KP-10 centers on two use cases. First, men using suppressive regimens — testosterone replacement therapy, anabolic steroid cycles, or GnRH-axis-affecting drugs — sometimes use KP-10 during \"post-cycle\" recovery phases on the theory that stimulating endogenous GnRH release may accelerate HPG axis recovery faster than the conventional Gonadorelin (GnRH) or HCG (Human Chorionic Gonadotropin) approaches. The evidence base for this use is thin — kisspeptin's efficacy in restoring suppressed axes after exogenous androgens has not been formally studied — but mechanistically plausible. Second, some researchers and a small community of users are interested in kisspeptin's effects on sexual desire and mood, which appear to be separable from its reproductive effects and mediated by kisspeptin receptor expression in limbic structures like the amygdala ([Comninos et al., 2017]). KP-10 is a legitimate research tool with meaningful clinical promise and an unusually well-characterized physiological mechanism. Unlike many grey-market peptides, the clinical evidence base is growing and the safety profile in short-term human trials at reproductive-axis doses has been clean. This entry covers KP-10's known biology, its current and investigational uses, and the considerable uncertainties that remain — particularly around long-term dosing, optimal regimens for axis recovery, and whether peripheral KP-10 administration reproduces the physiological effects of endogenous kisspeptin neuron firing.", "url": "https://www.bodyhackguide.co/compound/kisspeptin-10", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "39.99", "highPrice": "54.99", "priceCurrency": "USD", "offerCount": "3", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "39.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/kisspeptin-10/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "Kisspeptin-10 5mg vial" }, { "@type": "Offer", "price": "39.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://optimumformula.co/product/kisspeptin-10/?ref=ruyhjwqh", "seller": { "@type": "Organization", "name": "Optimum Formula", "url": "https://optimumformula.co" }, "name": "Kisspeptin-10 10mg vial" }, { "@type": "Offer", "price": "54.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/kisspeptin/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Kisspeptin-10", "description": "Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date. The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Its true reproductive function wasn't understood until 2003, when two independent research groups — one led by Nicolas de Roux in Paris and another by Stephanie Seminara at Massachusetts General Hospital — discovered that loss-of-function mutations in the G-protein-coupled receptor GPR54 (now named KISS1R) caused hypogonadotropic hypogonadism with failure of puberty. This finding transformed kisspeptin from an obscure tumor-biology gene into the gatekeeper of the entire hypothalamic-pituitary-gonadal (HPG) axis (de Roux et al., 2003, Seminara et al., 2003). Kisspeptin is synthesized as a 145-amino-acid precursor prohormone that is processed into several bioactive peptides: kisspeptin-54 (KP-54, the longest form), kisspeptin-14, kisspeptin-13, and kisspeptin-10. KP-10 retains essentially all of the biological potency of the parent molecule at the KISS1R receptor, making it the most practical form for research and therapeutic exploration — it is smaller, more stable, easier to synthesize, and equally efficacious. Kisspeptin neurons in the hypothalamus (located in the arcuate nucleus and the preoptic area / AVPV) project to GnRH neurons and release kisspeptin as the essential upstream stimulus that drives GnRH release. Without kisspeptin signaling, GnRH neurons fire infrequently or not at all, and the entire reproductive axis — LH, FSH, testosterone, estrogen, ovulation, spermatogenesis — shuts down. This is why congenital KISS1R mutations cause such a dramatic reproductive phenotype despite the rest of the HPG axis being intact ([Messager et al., 2005]). In current clinical and research practice, kisspeptin (usually as KP-10 or KP-54) is being investigated for a range of reproductive applications: as a diagnostic probe for the integrity of the HPG axis (an alternative to or supplement to GnRH stimulation testing), as an ovulation trigger in in-vitro fertilization cycles (where it may reduce ovarian hyperstimulation syndrome risk compared to hCG), as a therapy for hypothalamic amenorrhea and functional hypothalamic hypogonadism, and as an investigational treatment for hypoactive sexual desire disorder (HSDD), with emerging work on mood and anxiety effects as well. Kisspeptin is not currently approved for any indication in the United States, but Phase II data from Imperial College London and other centers have been promising enough that pharmaceutical development is underway ([Dhillo et al., 2005], [Abbara et al., 2015]). Off-label and peptide-community interest in KP-10 centers on two use cases. First, men using suppressive regimens — testosterone replacement therapy, anabolic steroid cycles, or GnRH-axis-affecting drugs — sometimes use KP-10 during \"post-cycle\" recovery phases on the theory that stimulating endogenous GnRH release may accelerate HPG axis recovery faster than the conventional Gonadorelin (GnRH) or HCG (Human Chorionic Gonadotropin) approaches. The evidence base for this use is thin — kisspeptin's efficacy in restoring suppressed axes after exogenous androgens has not been formally studied — but mechanistically plausible. Second, some researchers and a small community of users are interested in kisspeptin's effects on sexual desire and mood, which appear to be separable from its reproductive effects and mediated by kisspeptin receptor expression in limbic structures like the amygdala ([Comninos et al., 2017]). KP-10 is a legitimate research tool with meaningful clinical promise and an unusually well-characterized physiological mechanism. Unlike many grey-market peptides, the clinical evidence base is growing and the safety profile in short-term human trials at reproductive-axis doses has been clean. This entry covers KP-10's known biology, its current and investigational uses, and the considerable uncertainties that remain — particularly around long-term dosing, optimal regimens for axis recovery, and whether peripheral KP-10 administration reproduces the physiological effects of endogenous kisspeptin neuron firing.", "lastReviewed": "2026-05-04T11:34:42.782+00:00", "url": "https://www.bodyhackguide.co/compound/kisspeptin-10", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Kisspeptin-10", "alternateName": [ "Kisspeptin" ], "description": "Kisspeptin-10 (KP-10, metastin 45-54) is the C-terminal decapeptide fragment of kisspeptin, a neuropeptide product of the KISS1 gene that has emerged over the past two decades as the master regulator of reproductive endocrinology in humans and all other vertebrates studied to date. The KISS1 gene was originally cloned in 1996 in Hershey, Pennsylvania (and named after the town's iconic Hershey Kiss), initially as a metastasis-suppressor gene in melanoma cell lines. Its true reproductive function wasn't understood until 2003, when two independent research groups — one led by Nicolas de Roux in Paris and another by Stephanie Seminara at Massachusetts General Hospital — discovered that loss-of-function mutations in the G-protein-coupled receptor GPR54 (now named KISS1R) caused hypogonadotropic hypogonadism with failure of puberty. This finding transformed kisspeptin from an obscure tumor-biology gene into the gatekeeper of the entire hypothalamic-pituitary-gonadal (HPG) axis (de Roux et al., 2003, Seminara et al., 2003). Kisspeptin is synthesized as a 145-amino-acid precursor prohormone that is processed into several bioactive peptides: kisspeptin-54 (KP-54, the longest form), kisspeptin-14, kisspeptin-13, and kisspeptin-10. KP-10 retains essentially all of the biological potency of the parent molecule at the KISS1R receptor, making it the most practical form for research and therapeutic exploration — it is smaller, more stable, easier to synthesize, and equally efficacious. Kisspeptin neurons in the hypothalamus (located in the arcuate nucleus and the preoptic area / AVPV) project to GnRH neurons and release kisspeptin as the essential upstream stimulus that drives GnRH release. Without kisspeptin signaling, GnRH neurons fire infrequently or not at all, and the entire reproductive axis — LH, FSH, testosterone, estrogen, ovulation, spermatogenesis — shuts down. This is why congenital KISS1R mutations cause such a dramatic reproductive phenotype despite the rest of the HPG axis being intact ([Messager et al., 2005]). In current clinical and research practice, kisspeptin (usually as KP-10 or KP-54) is being investigated for a range of reproductive applications: as a diagnostic probe for the integrity of the HPG axis (an alternative to or supplement to GnRH stimulation testing), as an ovulation trigger in in-vitro fertilization cycles (where it may reduce ovarian hyperstimulation syndrome risk compared to hCG), as a therapy for hypothalamic amenorrhea and functional hypothalamic hypogonadism, and as an investigational treatment for hypoactive sexual desire disorder (HSDD), with emerging work on mood and anxiety effects as well. Kisspeptin is not currently approved for any indication in the United States, but Phase II data from Imperial College London and other centers have been promising enough that pharmaceutical development is underway ([Dhillo et al., 2005], [Abbara et al., 2015]). Off-label and peptide-community interest in KP-10 centers on two use cases. First, men using suppressive regimens — testosterone replacement therapy, anabolic steroid cycles, or GnRH-axis-affecting drugs — sometimes use KP-10 during \"post-cycle\" recovery phases on the theory that stimulating endogenous GnRH release may accelerate HPG axis recovery faster than the conventional Gonadorelin (GnRH) or HCG (Human Chorionic Gonadotropin) approaches. The evidence base for this use is thin — kisspeptin's efficacy in restoring suppressed axes after exogenous androgens has not been formally studied — but mechanistically plausible. Second, some researchers and a small community of users are interested in kisspeptin's effects on sexual desire and mood, which appear to be separable from its reproductive effects and mediated by kisspeptin receptor expression in limbic structures like the amygdala ([Comninos et al., 2017]). KP-10 is a legitimate research tool with meaningful clinical promise and an unusually well-characterized physiological mechanism. Unlike many grey-market peptides, the clinical evidence base is growing and the safety profile in short-term human trials at reproductive-axis doses has been clean. This entry covers KP-10's known biology, its current and investigational uses, and the considerable uncertainties that remain — particularly around long-term dosing, optimal regimens for axis recovery, and whether peripheral KP-10 administration reproduces the physiological effects of endogenous kisspeptin neuron firing.", "activeIngredient": "Kisspeptin-10", "mechanismOfAction": "Kisspeptin-10 signals through a single G-protein-coupled receptor, KISS1R (formerly GPR54), expressed prominently on GnRH neurons in the hypothalamus and at lower levels in multiple peripheral tissues including placenta, gonads, and the central nervous system reward circuitry. The pharmacology is elegant and relatively simple in mechanism but drives a complex downstream physiology: Primary Hypothalamic Effect — GnRH Release: KISS1R activation is coupled predominantly to Gαq/11, which activates phospholipase C, generates inositol trisphosphate (IP3) and diacylglycerol (DAG), raises intracellular calcium, and triggers GnRH release from GnRH neuron terminals in the median eminence. Kisspeptin is currently understood to be the obligate upstream driver of pulsatile GnRH release — the GnRH neurons themselves generate the pulse timing, but kisspeptin input controls whether and how strongly they fire. Under physiological conditions, kisspeptin neurons in the arcuate nucleus (the \"KNDy\" neurons, which also express neurokinin B and dynorphin) fire synchronously to generate GnRH pulses, while kisspeptin neurons in the preoptic area (AVPV) drive the GnRH surge responsible for the mid-cycle LH surge in females. Downstream HPG Axis Activation: GnRH released from the median eminence travels through the hypophyseal portal circulation to the anterior pituitary, where it stimulates gonadotroph cells to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates gonadal testosterone or estrogen production and triggers ovulation in females; FSH drives spermatogenesis in males and follicular development in females. The entire cascade — KP-10 → GnRH → LH/FSH → gonadal steroids → gametogenesis — takes roughly 20-60 minutes from IV or SC kisspeptin administration to measurable LH/FSH rise in plasma. Selectivity and Signaling Bias: KP-10 is a high-affinity full agonist at KISS1R with IC50 in the low-nanomolar range. There is no significant cross-reactivity with other GPCRs. Signaling bias studies suggest that kisspeptin preferentially engages Gαq pathways over β-arrestin recruitment, which may contribute to its relatively favorable desensitization profile compared to GnRH analogs. Continuous high-dose kisspeptin exposure does eventually produce GnRH-axis downregulation, but pulsatile or intermittent dosing appears to maintain responsiveness. Extrapituitary Effects: Limbic system (amygdala, hippocampus, cingulate cortex): KISS1R expression in limbic structures mediates kisspeptin's effects on sexual desire, emotional processing, and mood. Comninos and colleagues at Imperial College have shown using fMRI that kisspeptin administration in men enhances brain activity in reward/arousal circuits in response to sexual and romantic cues, and attenuates activity in regions associated with negative mood and anxiety ([Comninos et al., 2017]). Gonads (direct): KISS1R is expressed on theca and granulosa cells of the ovary and on Leydig cells of the testis; direct local kisspeptin signaling may modulate steroidogenesis and gamete maturation, though the physiological significance of these peripheral actions in kisspeptin-treated subjects is uncertain. Placenta: Kisspeptin is produced in large amounts by trophoblasts and is thought to regulate trophoblast invasion and placental development. This is why plasma kisspeptin concentrations rise dramatically in pregnancy. Pharmacokinetics: KP-10 administered subcutaneously or intravenously has a plasma half-life of approximately 4 minutes — extremely short, reflecting rapid peptidase degradation. Despite this short half-life, the downstream LH/FSH response lasts 1-2 hours because the pituitary gonadotrophs require time to transcribe and secrete the hormones triggered by the initial GnRH pulse. Continuous infusion or repeated boluses produce sustained axis activation; single doses produce a single pulse-like LH/FSH rise. This short half-life is why kisspeptin preparations are usually administered either as continuous subcutaneous infusions (for ovulation induction or sustained axis stimulation) or as frequent bolus doses (for pulsatile stimulation mimicking endogenous physiology). Longer-Acting Forms: Researchers have developed both KP-54 (which has slightly longer half-life but still on the order of 30 minutes) and engineered kisspeptin analogs with PEGylation or other half-life-extending modifications. MVT-602 (from Myovant Sciences) is a kisspeptin analog with an approximate 60-90 minute half-life being investigated for clinical use. For most peptide-community use, plain KP-10 remains the most accessible form.", "dosageForm": "vial", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What exactly does kisspeptin do that makes it so important?", "acceptedAnswer": { "@type": "Answer", "text": "Kisspeptin is the master upstream regulator of the entire reproductive axis. It stimulates GnRH neurons in the hypothalamus to release GnRH, which then drives LH and FSH release from the pituitary, which then drives testosterone, estrogen, spermatogenesis, and ovulation from the gonads. Without kisspeptin signaling, the whole axis goes silent - people born with inactivating mutations in the kisspeptin receptor (KISS1R) fail to enter puberty. Because kisspeptin sits at the top of this cascade, exogenous kisspeptin can drive the entire axis downstream when administered, making it uniquely powerful among reproductive peptides." } }, { "@type": "Question", "name": "How is KP-10 different from KP-54?", "acceptedAnswer": { "@type": "Answer", "text": "Both are endogenously produced kisspeptin peptides - KP-54 is the longer precursor cleavage product (54 amino acids), and KP-10 is the C-terminal decapeptide that retains essentially all the biological activity. KP-10 has a shorter plasma half-life (~4 minutes vs ~30 minutes for KP-54) but is functionally equivalent at the receptor. For most peptide-community use, KP-10 is more commonly available and equally effective for axis stimulation. Clinical research often uses KP-54 for applications like ovulation induction where the slightly longer half-life simplifies dosing." } }, { "@type": "Question", "name": "Can I use KP-10 during an active anabolic cycle?", "acceptedAnswer": { "@type": "Answer", "text": "It will not work during active high-dose androgen administration. Exogenous androgens produce powerful negative feedback at both hypothalamus and pituitary, and this suppression overwhelms any upstream kisspeptin stimulation. KP-10 is useful during recovery phases (after exogenous androgens are cleared, typically 2-4 weeks post-cycle depending on ester) but not during active suppression. HCG, which acts directly at Leydig cell LH receptors in the testis and bypasses central suppression, is the appropriate on-cycle support for testicular function - kisspeptin becomes relevant afterward." } }, { "@type": "Question", "name": "How quickly will I feel KP-10 working?", "acceptedAnswer": { "@type": "Answer", "text": "This depends on indication. For axis recovery after exogenous androgen suppression, effects are measured in lab trends over weeks - LH and FSH rises can be seen within days of starting, testosterone follows over 2-4 weeks, and full axis normalization often takes 6-12 weeks. Subjectively, most users notice returning morning erections, libido, and energy gradually over the first month rather than any dramatic acute change. For the central desire/HSDD effects, acute subjective changes (libido, emotional engagement) often occur within 1-2 hours of dosing. The axis and the limbic effects operate on different timescales." } }, { "@type": "Question", "name": "Is KP-10 safer than HCG or clomiphene for axis recovery?", "acceptedAnswer": { "@type": "Answer", "text": "Short answer: side-effect profiles differ, and KP-10 looks cleanest in published trials, but no head-to-head long-term comparison study has been done. HCG maintains Leydig cell function during cycle but can desensitize LH receptors with prolonged use and does not address hypothalamic suppression. Clomiphene/enclomiphene act at the estrogen receptor and have well-documented vision and mood side effects in some users. KP-10 acts at the hypothalamus through a different mechanism without the desensitization or SERM side-effect concerns, but the long-term safety of repeated kisspeptin dosing has not been established. Most users of rigorous recovery protocols combine modalities rather than relying on any single agent." } }, { "@type": "Question", "name": "Will KP-10 make me fertile if I've been trying to conceive?", "acceptedAnswer": { "@type": "Answer", "text": "Possibly yes, for both men and women. In men with suppressed axes from exogenous androgens or functional causes, kisspeptin-driven LH/FSH restoration can rebuild spermatogenesis over 3-6 months (one full spermatogenesis cycle). In women with functional hypothalamic amenorrhea, kisspeptin can restore ovulation; published trials have demonstrated live births following kisspeptin-triggered ovulation in IVF cycles. However, fertility is complicated and requires the entire reproductive system to be intact. Kisspeptin fixes upstream signaling but cannot compensate for primary gonadal failure, severe oligospermia from structural causes, or uterine/tubal factors. Fertility work should be medically supervised." } }, { "@type": "Question", "name": "Does KP-10 help with libido even if my testosterone is normal?", "acceptedAnswer": { "@type": "Answer", "text": "Research suggests yes. Kisspeptin's effects on sexual desire and romantic processing operate through limbic brain regions (amygdala, hippocampus) that are pharmacologically separate from the HPG axis. Imperial College studies have shown fMRI evidence of enhanced sexual arousal circuit activation from kisspeptin even in eugonadal men, and clinical trials in women with HSDD have shown improvements in subjective desire that are not driven by testosterone or estrogen changes. This central mechanism appears to be distinct from the HPG-axis mechanism and is why kisspeptin is being pursued as a potential HSDD treatment. In practical use, some people with normal hormones experience meaningful subjective libido response to kisspeptin; others do not - individual response varies." } }, { "@type": "Question", "name": "What about kisspeptin and mood or anxiety?", "acceptedAnswer": { "@type": "Answer", "text": "Preliminary research suggests kisspeptin may have anxiolytic effects and improve mood regulation in some populations, mediated through limbic kisspeptin receptors. Small trials and case studies have reported improvements in self-reported anxiety and mood during kisspeptin administration. However, this is not a clinical indication and the evidence base is much smaller than for reproductive effects. No one should substitute kisspeptin for evidence-based mental health treatment. If users notice mood benefits alongside reproductive effects, this is consistent with the emerging science but should not be the primary reason for use." } }, { "@type": "Question", "name": "Do I need to cycle KP-10?", "acceptedAnswer": { "@type": "Answer", "text": "It depends on how you dose. This matters because human trials have actually shown clear tachyphylaxis under some schedules: twice-daily subcutaneous kisspeptin-54 injections in women with hypothalamic amenorrhea largely abolished the LH and FSH response within about two weeks of high-frequency bolus dosing. Spacing the same peptide out to twice-weekly avoided most of that desensitization while still raising reproductive hormones over eight weeks, and short studies of continuous KP-10 infusion have maintained responses - so the receptor does not inevitably desensitize, but frequent, sustained, high-dose bolus exposure clearly can blunt it. Because long-term data are absent, spacing doses and using defined cycles (for example, running an 8-12 week axis-recovery block around a specific goal and then discontinuing, rather than dosing indefinitely) is the prudent, conservative approach." } }, { "@type": "Question", "name": "Can women use KP-10 for axis recovery after hormonal contraceptive suppression?", "acceptedAnswer": { "@type": "Answer", "text": "Possibly. Some women experience prolonged menstrual cycle irregularity after stopping long-term hormonal contraception, often reflecting functional hypothalamic suppression. Kisspeptin has shown efficacy in restoring cycles in hypothalamic amenorrhea trials and may theoretically help in post-contraceptive axis recovery. However, the evidence base for this specific application is thinner than for men's post-cycle recovery. Women considering kisspeptin for cycle restoration should ideally work with a reproductive endocrinologist and ensure that other causes of irregular cycles (thyroid, prolactinoma, PCOS) have been excluded. Pregnancy possibility during kisspeptin use in cycling women must be considered." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```